These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 37165594)

  • 1. The mTOR Signaling Pathway and mTOR Inhibitors in Cancer: Next-generation Inhibitors and Approaches.
    Ihlamur M; Akgul B; Zengin Y; Korkut ŞV; Kelleci K; Abamor EŞ
    Curr Mol Med; 2024; 24(4):478-494. PubMed ID: 37165594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
    Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
    Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Cytoprotective and Cytotoxic Functions of Autophagy in Response to mTOR Inhibitors.
    Elshazly AM; Elzahed AA; Gewirtz DA
    Front Biosci (Landmark Ed); 2024 Jun; 29(6):231. PubMed ID: 38940039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
    Chen D; Lin X; Zhang C; Liu Z; Chen Z; Li Z; Wang J; Li B; Hu Y; Dong B; Shen L; Ji J; Gao J; Zhang X
    Cell Death Dis; 2018 Jan; 9(2):123. PubMed ID: 29374144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting mTOR and Metabolism in Cancer: Lessons and Innovations.
    Magaway C; Kim E; Jacinto E
    Cells; 2019 Dec; 8(12):. PubMed ID: 31817676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and future directions in mammalian target of rapamycin inhibitors development.
    Fasolo A; Sessa C
    Expert Opin Investig Drugs; 2011 Mar; 20(3):381-94. PubMed ID: 21299441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer.
    He J; McLaughlin RP; van der Noord V; Foekens JA; Martens JWM; van Westen G; Zhang Y; van de Water B
    Breast Cancer Res Treat; 2019 Nov; 178(2):263-274. PubMed ID: 31388935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
    Grzybowska-Izydorczyk O; Smolewski P
    Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current treatment strategies for inhibiting mTOR in cancer.
    Chiarini F; Evangelisti C; McCubrey JA; Martelli AM
    Trends Pharmacol Sci; 2015 Feb; 36(2):124-35. PubMed ID: 25497227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML.
    Herschbein L; Liesveld JL
    Blood Rev; 2018 May; 32(3):235-248. PubMed ID: 29276026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updates of mTOR inhibitors.
    Zhou H; Luo Y; Huang S
    Anticancer Agents Med Chem; 2010 Sep; 10(7):571-81. PubMed ID: 20812900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
    Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
    PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mTOR inhibitors in the treatment of cancer.
    Fasolo A; Sessa C
    Expert Opin Investig Drugs; 2008 Nov; 17(11):1717-34. PubMed ID: 18922108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting mTOR for cancer therapy.
    Hua H; Kong Q; Zhang H; Wang J; Luo T; Jiang Y
    J Hematol Oncol; 2019 Jul; 12(1):71. PubMed ID: 31277692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting mTOR for fighting diseases: A revisited review of mTOR inhibitors.
    Xu T; Sun D; Chen Y; Ouyang L
    Eur J Med Chem; 2020 Aug; 199():112391. PubMed ID: 32416459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mTOR signaling pathway and mTOR inhibitors in cancer therapy.
    Gomez-Pinillos A; Ferrari AC
    Hematol Oncol Clin North Am; 2012 Jun; 26(3):483-505, vii. PubMed ID: 22520976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
    Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
    Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTOR kinase inhibitors as potential cancer therapeutic drugs.
    Sun SY
    Cancer Lett; 2013 Oct; 340(1):1-8. PubMed ID: 23792225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [mTOR inhibitor].
    Muro K
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):7-11. PubMed ID: 21368454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiating mTOR inhibitors in renal cell carcinoma.
    Pal SK; Quinn DI
    Cancer Treat Rev; 2013 Nov; 39(7):709-19. PubMed ID: 23433636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.